# WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Source: https://onco.cc/trials/nct04644289/  
OnCo record `nct04644289` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olaparib, Durvalumab in ovarian cancer, run by AGO Research GmbH, now recruiting.

## Summary

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC is a phase 2 interventional study registered as NCT04644289 by AGO Research GmbH, with 60 participants planned, started 2022-05-05 and due to reach its primary completion in 2028-01. Interventions recorded: olaparib, durvalumab. Conditions listed: Epithelial Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04644289
- Phase: 2
- Setting: Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer (EOC)
- Sponsor: AGO Research GmbH
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04644289: https://clinicaltrials.gov/study/NCT04644289

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/)

---
JSON: https://onco.cc/api/v1/entities/nct04644289.json